Abivax SA reports developments as a clinical-stage biotechnology company developing therapeutics that modulate immune response in chronic inflammatory diseases. Its news centers on obefazimod (ABX464), the company’s lead therapeutic candidate, including clinical and preclinical data in inflammatory bowel disease, Phase 3 ABTECT work in moderately to severely active ulcerative colitis, and related safety, efficacy, biomarker, and patient-reported outcome analyses.
Recurring updates also cover financial results, annual and regulatory reporting in France and the United States, American Depositary Share offerings, royalty certificate obligations, public-company governance, annual meeting materials, and trading references for its Euronext Paris and Nasdaq-listed securities.
Abivax (Euronext: ABVX, Nasdaq: ABVX), a clinical-stage biotechnology company, has been selected to join the CAC Mid 60 and SBF 120 indices following Euronext Paris's annual review. The inclusion will become effective on September 19, 2025, after market close.
The company, which focuses on developing therapeutics for chronic inflammatory diseases, expects this inclusion to enhance its visibility and broaden its investor base, particularly among institutional investors and index-linked funds. CEO Marc de Garidel highlighted this achievement as a validation of the company's strategic vision and execution capabilities.
Abivax (NASDAQ/Euronext: ABVX) reported its H1 2025 financial results, highlighting increased R&D investments and significant capital raising activities. The company recorded an operating loss of EUR 93.7M, up from EUR 80.0M in H1 2024, primarily due to expanded R&D expenses of EUR 77.9M.
Key developments include successful completion of a $747.5M public offering in July 2025 and positive Phase 3 results from ABTECT trials for obefazimod in ulcerative colitis. The company's cash position stood at EUR 60.9M as of June 30, 2025, and with recent financing activities, Abivax expects to fund operations into Q4 2027.
Notable debt conversions occurred post-period, including Heights Capital Management's conversion of EUR 21.9M convertible notes and Kreos Capital's conversion of Tranche A convertible OCABSA.
Abivax (NASDAQ/Euronext: ABVX), a clinical-stage biotechnology company, has successfully closed its public offering of 11,679,400 American Depositary Shares (ADSs), including the full exercise of the underwriters' option. The offering generated gross proceeds of $747.5 million (€637.5 million), with estimated net proceeds of $700.3 million (€597.2 million) after deducting costs.
The company expects these proceeds, combined with existing cash, will extend its operational runway into Q4 2027, providing 12 months of cash following the planned NDA submission for Ulcerative Colitis, contingent on positive Phase 3 maintenance trial results. The offering was managed by Leerink Partners, Piper Sandler & Co., and Guggenheim Securities as joint bookrunners.
Abivax (NASDAQ:ABVX), a clinical-stage biotechnology company focused on chronic inflammatory diseases, announced the full exercise of underwriters' option to purchase 1,523,400 additional American Depositary Shares (ADSs) at $64.00 per ADS.
The additional shares bring the total offering to 11,679,400 ADSs, resulting in gross proceeds of $747.5 million (€637.5 million) and estimated net proceeds of $700.3 million (€597.2 million). The offering price represents a 21.0% premium over the volume-weighted average price of Ordinary Shares on Euronext Paris over the last three trading sessions.
The closing is expected on July 28, 2025, with the net proceeds to be applied proportionally to the same purposes as the base offering.
Abivax (Euronext Paris: ABVX), a clinical-stage biotechnology company, announced the resumption of trading for its ordinary shares on Euronext Paris effective July 24, 2025, at 3:30 p.m. CEST.
The trading halt, which began at 9:00 a.m. CEST on the same day, was implemented to facilitate the allocation process and pricing announcement of the company's American Depositary Shares (ADS) offering in the United States. Each ADS represents one ordinary share with a nominal value of €0.01.
Abivax (NASDAQ:ABVX) has announced the pricing of its public offering of 10,156,000 American Depositary Shares (ADSs) at $64.00 per ADS, aiming to raise approximately $650 million. The company has also granted underwriters a 30-day option to purchase up to 1,523,400 additional ADSs.
The offering price represents a 21% premium over the volume-weighted average price of Ordinary Shares on Euronext Paris. The proceeds will primarily fund the clinical development of obefazimod for Ulcerative Colitis ($140-185 million) and Crohn's Disease ($30-65 million). Combined with current cash reserves of $71.4 million, this funding is expected to extend operations into Q4 2027.
The offering will result in approximately 16% dilution of share capital, or 18.4% if the underwriters' option is fully exercised. A 60-day lock-up period applies to both company executives and the company itself.
Abivax (Euronext Paris: ABVX), a clinical-stage biotechnology company, has announced a temporary trading halt of its ordinary shares on Euronext Paris starting July 24, 2025, at 9:00 a.m. CEST. The suspension is related to the company's previously announced public offering of American Depositary Shares (ADS) in the United States.
The trading halt will allow for investor allocation confirmations and pricing announcement of the U.S. offering. Each ADS represents one ordinary share with a nominal value of €0.01. Trading is expected to resume on the same day at approximately 3:30 p.m. CEST.
Abivax (NASDAQ:ABVX) has announced the launch of a significant $400 million (€340 million) public offering of American Depositary Shares (ADSs) in the United States. Each ADS represents one ordinary share of the company. The offering includes a 30-day option for underwriters to purchase up to 15% additional ADSs.
The company plans to use the proceeds primarily for: 23% for obefazimod development in Ulcerative Colitis, 5% for Crohn's Disease development, and 72% for working capital and general corporate purposes. As of June 30, 2025, Abivax had cash reserves of $71.4 million, sufficient to fund operations into Q4 2025.
Additionally, Heights Capital Management has submitted a notice to convert 150 convertible notes (€9.4 million) into 394,447 new ordinary shares at €23.7674 per share, with issuance expected around July 29, 2025.
Abivax (NASDAQ:ABVX) announced positive Phase 3 results from its ABTECT-1 and ABTECT-2 trials evaluating obefazimod, a first-in-class oral miR-124 enhancer, for treating moderate to severe ulcerative colitis. The 50mg once-daily dose achieved a compelling pooled 16.4% placebo-adjusted clinical remission rate at Week 8.
Key highlights include: 19.3% placebo-adjusted remission in ABTECT-1 and 13.4% in ABTECT-2, meeting all primary and secondary endpoints. The trials involved 1,275 patients across 600 sites in 36 countries, with 47.3% having inadequate response to prior advanced therapy. The drug demonstrated favorable safety with no new safety signals.
The company plans to submit FDA and EMA applications in H2 2026, pending successful maintenance trial results expected in Q2 2026.